Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/0004-282x20140102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Whole blood concentrations of fingolimod and its pharmacologically active metabolite fingolimod phosphate obtained during routine health care of patients with multiple sclerosis.
Mult Scler Relat Disord
December 2024
Department of Clinical Pharmacology, Faculty of Medicine, University of Ostrava; Department of Clinical Pharmacology, Institute of Laboratory Medicine, University Hospital Ostrava, Czech Republic.
Background: Fingolimod is a first-in-class, orally administered drug indicated for the treatment of relapsing-remitting multiple sclerosis. It acts as an immunomodulator, is classified as a "disease-modifying therapy", and its main mechanism of action is the modulation of sphingosine-1-phosphate receptors. In this prospective pilot study, whole blood concentrations of fingolimod and fingolimod phosphate obtained during routine health care were measured.
View Article and Find Full Text PDFSevere Disease Activation after Fingolimod Discontinuation in a Pediatric Multiple Sclerosis Patient: A Case Report and Literature Review.
Neuropediatrics
December 2024
Department of Pediatric Neurology, Jena University Hospital, Jena, Germany.
Adult reports of unexpected severe disease worsening, often termed "rebound," shortly after discontinuing fingolimod in a subset of patients with multiple sclerosis (MS), have grown over the last decade. This phenomenon, however, remains poorly described in pediatric MS patients. We present findings of a 15-year-old who experienced a debilitating relapse 4 weeks after stopping fingolimod to switch to ocrelizumab.
View Article and Find Full Text PDFApproach to Managing the Initial Presentation of Multiple Sclerosis: A Worldwide Practice Survey.
Neurol Clin Pract
February 2025
Department of Clinical Neurosciences (JIR, AG), University of Calgary, Canada; Neuroimmunology Centre (JIR, TK), Department of Neurology, Royal Melbourne Hospital; Clinical Outcomes Research Unit (JIR, TK), Department of Medicine, University of Melbourne, Australia; Hotchkiss Brain Institute (JIR, AG), University of Calgary, Canada; and Hasbro Children's Hospital (LB), Brown University, Providence, RI.
Article Synopsis
- Multiple sclerosis (MS) disease-modifying therapies (DMTs) are expanding, and early high-efficacy treatments may provide better outcomes, prompting a study on management strategies for relapsing-remitting MS.
- A global electronic survey regarding a 37-year-old woman with optic neuritis gathered responses from 153 participants across 42 countries, revealing a strong preference for high-dose intravenous corticosteroids and a notable inclination toward high-efficacy DMTs.
- Results showed that 56.6% of respondents preferred high-efficacy therapies, with significant variation in treatment approaches, indicating ongoing debates about the best management strategies for MS.
Long-term effects of siponimod on cardiovascular and autonomic nervous system in secondary progressive multiple sclerosis.
Front Pharmacol
September 2024
Center of Clinical Neuroscience, Department of Neurology, University Hospital Carl Gustav Carus, Dresden, Technical University of Dresden, Dresden, Germany.
Background: Siponimod, a second-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, represents an important therapeutic choice for active secondary progressive multiple sclerosis (SPMS). Besides the beneficial immunomodulatory effects, siponimod impacts cardiovascular function through S1PR1 modulation. Short-term vagomimetic effects on cardiac activity have proved to be mitigated by dose titration.
View Article and Find Full Text PDFDissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P receptor-mediated G-protein activation in a mouse model of sciatic nerve injury.
Neuropharmacology
December 2024
Department of Pharmacology and Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, USA. Electronic address:
Sphingosine-1-phosphate (S1P) receptor (S1PR) agonists, such as fingolimod (FTY720), alleviate nociception in preclinical pain models by either activation (agonism) or inhibition (functional antagonism) of S1PR type-1 (S1PR1). However, the dose-dependence and temporal relationship between reversal of nociception and modulation of S1PR1 signaling has not been systematically investigated. This study examined the relationship between FTY720-induced antinociception and S1PR1 adaptation using a sciatic nerve chronic constriction injury (CCI) model of neuropathic pain in male and female C57Bl/6J mice.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!